These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28664229)

  • 1. Response criteria of tolvaptan for the treatment of hepatic edema.
    Hiramine Y; Uojima H; Nakanishi H; Hiramatsu A; Iwamoto T; Kimura M; Kawaratani H; Terai S; Yoshiji H; Uto H; Sakaida I; Izumi N; Okita K; Koike K
    J Gastroenterol; 2018 Feb; 53(2):258-268. PubMed ID: 28664229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients.
    Nakagawa A; Atsukawa M; Tsubota A; Kondo C; Okubo T; Arai T; Itokawa N; Narahara Y; Iwakiri K
    World J Gastroenterol; 2016 Jun; 22(21):5104-13. PubMed ID: 27275103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study).
    Sakaida I; Terai S; Kurosaki M; Okada M; Hirano T; Fukuta Y
    J Gastroenterol; 2020 Aug; 55(8):800-810. PubMed ID: 32388692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites.
    Sagawa E; Okubo H; Ando H; Sorin Y; Kanazawa R; Nakadera E; Fukada H; Kokubu S; Miyazaki A
    J Pharmacol Sci; 2019 Apr; 139(4):373-376. PubMed ID: 30857764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term administration of Tolvaptan to patients with decompensated cirrhosis.
    Kanayama K; Chiba T; Kobayashi K; Koroki K; Maruta S; Kanzaki H; Kusakabe Y; Saito T; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Ooka Y; Nakamoto S; Yasui S; Kanda T; Maruyama H; Kato J; Kato N
    Int J Med Sci; 2020; 17(7):874-880. PubMed ID: 32308540
    [No Abstract]   [Full Text] [Related]  

  • 6. Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study.
    Iwatani H; Kawabata H; Sakaguchi Y; Yamamoto R; Hamano T; Rakugi H; Isaka Y
    Nephron; 2015; 130(1):8-12. PubMed ID: 25926290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolvaptan Efficiently Reduces Intracellular Fluid: Working Toward a Potential Treatment Option for Cellular Edema.
    Kawabata H; Iwatani H; Yamamichi Y; Shirahase K; Nagai N; Isaka Y
    Intern Med; 2019 Mar; 58(5):639-642. PubMed ID: 30449775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different Effects on Fluid Distribution between Tolvaptan and Furosemide in a Liver Cirrhosis Patient with Chronic Kidney Disease.
    Nagayama I; Masuda T; Nakagawa S; Murakami T; Ohara K; Matsuoka R; Kobayashi T; Maeshima A; Akimoto T; Saito O; Muto S; Nagata D
    Intern Med; 2019 Jun; 58(11):1587-1591. PubMed ID: 30713322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):461-70. PubMed ID: 24678622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis.
    Sakaida I; Terai S; Nakajima K; Shibasaki Y; Tachikawa S; Tsubouchi H
    J Gastroenterol; 2017 Feb; 52(2):229-236. PubMed ID: 27379386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites.
    Iwamoto T; Maeda M; Saeki I; Hidaka I; Tajima K; Ishikawa T; Takami T; Sakaida I
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1231-1235. PubMed ID: 30370940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.
    Atsukawa M; Tsubota A; Takaguchi K; Toyoda H; Iwasa M; Ikegami T; Chuma M; Nozaki A; Uojima H; Hiraoka A; Fukunishi S; Yokohama K; Tada T; Kato K; Abe H; Tani J; Okubo H; Watanabe T; Hattori N; Tsutsui A; Senoh T; Yoshida Y; Okubo T; Itokawa N; Nakagawa-Iwashita A; Kondo C; Arai T; Michitaka K; Iio E; Kumada T; Tanaka Y; Takei Y; Iwakiri K
    J Gastroenterol Hepatol; 2020 Jul; 35(7):1229-1237. PubMed ID: 31881554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema.
    Atsukawa M; Tsubota A; Kato K; Abe H; Shimada N; Asano T; Ikegami T; Koeda M; Okubo T; Arai T; Nakagawa-Iwashita A; Yoshida Y; Hayama K; Itokawa N; Kondo C; Chuganji Y; Matsuzaki Y; Iwakiri K
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1256-1263. PubMed ID: 29215154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of continued administration of tolvaptan on cirrhotic patients with ascites.
    Kogiso T; Sagawa T; Kodama K; Taniai M; Tokushige K
    BMC Pharmacol Toxicol; 2018 Dec; 19(1):87. PubMed ID: 30563565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
    Komiyama Y; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Yasui Y; Tamaki N; Takada H; Higuchi M; Gotou T; Kubota Y; Takaura K; Hayashi T; Oh W; Okada M; Enomoto N; Izumi N
    PLoS One; 2017; 12(3):e0174649. PubMed ID: 28362879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study.
    Shiba S; Chu PS; Nakamoto N; Yamataka K; Taniki N; Ojiro K; Yamaguchi A; Morikawa R; Yoshida A; Ikura A; Ebinuma H; Saito H; Kanai T
    BMC Gastroenterol; 2020 Mar; 20(1):53. PubMed ID: 32138675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial.
    Wang YF; Tang JT; Han T; Ding HG; Ye WJ; Wang MR; Cheng J; Yang YP; Chen CW; Xie Q; Mao Q; Niu JQ; Wang ZH; Wei Z; Chen YX; Zeng M; Mao YM
    J Dig Dis; 2018 Mar; 19(3):144-154. PubMed ID: 29389068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Tajiri K; Tokimitsu Y; Ito H; Atarashi Y; Kawai K; Minemura M; Yasumura S; Takahara T; Shimizu Y; Sugiyama T
    Dig Dis; 2018; 36(4):314-321. PubMed ID: 29852495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.
    Okita K; Sakaida I; Okada M; Kaneko A; Chayama K; Kato M; Sata M; Yoshihara H; Ono N; Murawaki Y
    J Gastroenterol; 2010 Sep; 45(9):979-87. PubMed ID: 20387081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.
    Namba M; Hiramatsu A; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Tsuge M; Imamura M; Chayama K
    J Gastroenterol; 2020 Feb; 55(2):217-226. PubMed ID: 31485782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.